Novo’s 2027 Price Cut to $675: Will You Actually Pay Less?

Here’s the headline and the asterisk in one breath. On January 1, 2027, Novo Nordisk will lower the list price of Wegovy, Ozempic, and Rybelsus to $675 a month, a cut of roughly 50% for Wegovy and 35% for Ozempic. That sounds like a windfall. For most people paying out of pocket, though, the price at checkout won’t move, because the cut applies to the list price, not the direct-to-patient self-pay price. If you’ve been buying Wegovy through NovoCare at around $349 a month, that number is expected to stay where it is. The cut helps a specific group, and it’s smaller than the percentage makes it look.

What’s actually changing

Novo announced in February 2026 that all doses of three semaglutide products will move to a single $675 monthly list price next January.

List price, also called the wholesale acquisition cost, is the sticker figure before rebates, insurance negotiations, or discounts. Almost nobody pays it directly. It matters mostly as the number your cost-sharing is calculated from when your insurance ties your payment to it.

Who this helps, and who it doesn’t

The people who benefit are those whose out-of-pocket cost is pegged to list price. That mainly means two groups: people on high-deductible health plans who pay the full negotiated price until they meet the deductible, and people with coinsurance benefit designs who pay a percentage of the drug’s price rather than a flat copay. For them, a lower starting number can mean real savings at the counter beginning in 2027.

The people who won’t see a change are those already paying a fixed amount. If you have a flat copay, your copay is set by your plan, not the list price. If you pay cash through NovoCare or a similar direct program, Novo has stated plainly that these list-price changes do not affect direct-to-patient self-pay pricing. And if you’re on the Medicare GLP-1 Bridge, your copay is a flat $50 regardless of any list-price move.

Why the cash price stays put

It helps to separate the two systems. The list-price-and-rebate system runs through pharmacy benefit managers and insurers, with large rebates flowing behind the scenes. Analysts expect Novo to offset much of the lower list price by trimming those rebates, which means the net price after rebates may barely change. The direct-to-patient system is a separate channel with its own set price, built to bypass that machinery. Lowering the list price doesn’t touch it. So the $675 figure and the $349 cash figure live in different worlds.

There’s a timing reason behind the date, too. January 1, 2027 is also when Medicare’s negotiated “maximum fair price” for semaglutide takes effect, reportedly around $274 for a 30-day supply within Medicare. Aligning the list-price cut with that moment lets the pricing across channels look less jarring, even though the cash and Medicare numbers were already heading down on their own tracks.

Consider a scenario where two people both take Wegovy. One has a high-deductible plan and pays the negotiated price out of pocket early in the year; in 2027, that early-year cost drops meaningfully. The other pays $349 cash through NovoCare; in 2027, they pay the same $349. Same drug, same headline, opposite experience.

Where this leaves cost-conscious patients

A $675 list price is still well above the lowest routes to the same molecule. Direct cash programs already sit below it, and compounded semaglutide generally sits below those. The clinical picture supports treating the molecule, not the label: in the STEP 2 trial, adults with type 2 diabetes and obesity lost about 9.6% of their body weight on semaglutide 2.4 mg versus about 3.4% on placebo, results that come from the active ingredient rather than the brand name on the box.

If you’re paying out of pocket, that’s the point to focus on. TrimRx connects you with licensed providers who prescribe semaglutide or tirzepatide when it’s clinically appropriate, and it bundles the provider visit and shipping into a flat monthly structure with no insurance required, with pricing from $179 to $1,579 depending on the medication and plan. Comparing that flat structure against a list price you may never actually pay is a more useful exercise than reacting to the $675 headline.

To see what your own out-of-pocket picture could look like, the free assessment quiz takes a few minutes.

This article is for educational purposes and is not medical or financial advice. Announced pricing can change before it takes effect, and your actual cost depends on your plan design, deductible, and pharmacy. Confirm current prices with the manufacturer and your insurer, and consult a licensed healthcare provider before starting any medication.